BC PharmaCare is looking for your input on sarilumab for the treatment of rheumatoid arthritis
Sarilumab (Kevzara™) is a fully human monoclonal antibody that targets IL-6, a protein central to the development of the signs and symptoms of rheumatoid arthritis. Sarilumab can be used alone or in combination with methotrexate or other traditional disease-modifying antirheumatic drugs (DMARDs). It is given by subcutaneous (under the skin) injection. The drug is now being considered for coverage under the British Columbia Ministry of Health’s PharmaCare program. Continue reading
Arthritis Broadcast Network (ABN) – powered by Arthritis Consumer Experts – All your arthritis news and information. All the time. Thanks to our fans, our most recent Facebook Live event reached over 23,000 people in just three days!
Arthritis Broadcast Network is honoured to be named one of the top 40 arthritis blogs and websites for people living with arthritis by Feedspot. Rankings are based on the following criteria: Continue reading
Each of us has the power to change arthritis—together, we can change the way arthritis is perceived by the public, portrayed in the media, and understood by government. As people with arthritis, and their family members and friends, the arthritis community is in a unique position to provide media, government, and healthcare decision-makers with the real story of arthritis.
But none of us can do this alone. One or two voices may be easy to ignore, but speaking together we are powerful. The voice of arthritis—the voices of all of the people who live with the disease, or care about someone who does—is strong and getting stronger every day.
Please take the time to view the interviews below on patient advocacy and learn what passionate people and patient organizations are doing to promote arthritis awareness. Learn the facts about arthritis, and about the discrimination that people with arthritis face every day. Think about your own story, or the story of someone you love. When you’re ready, join with us and take action.
Challenge the misperceptions. Speak up. Tell your story. Change arthritis.
The interviews below are conducted as part of the “CRA Interview Series 2017 – Facebook Live #CRArthritis Speaker’s Corner” event at the CRA Annual Scientific Meeting & AHPA Annual Meeting in Ottawa earlier this month. Continue reading
City of Ottawa and Aboriginal Peoples Television Network awarded for best arthritis workplaces in Canada
Award presentation to City of Ottawa (From left to right: Cheryl Koehn, ACE; Marianne Phillips, Director, Human Resources, Donna Gray, General Manager, Service Innovation and Performance Department, Mayor Jim Watson; Kelly Lendvoy, ACE)
(VANCOUVER) — To recognize the best arthritis workplace practices in Canada, Arthritis Consumer Experts (ACE) today announced the winners of its third annual search for Canada’s Best Workplaces for Employees Living with Arthritis.
Many Canadian workers struggle to find the right balance between work, family and personal responsibilities, particularly employees with chronic disease who are becoming an increasingly high proportion of the workforce due to aging, arthritis chief among them. Canadian employers who understand chronic disease, particularly the impact of a disease like arthritis, are implementing adaptations in their work environments to accommodate employees. Based on workplace insights shared by employees and company managers, ACE is awarding the City of Ottawa and Aboriginal Peoples Television Network for their arthritis awareness, prevention and benefits practices in the workplace.
Good news in British Columbia!
Tofacitinib (Xeljanz®) for the treatment of rheumatoid arthritis listed by BC PharmaCare
As of January 31st, tofacitinib (Xeljanz®) for the treatment of moderate to severe rheumatoid arthritis has been listed for coverage on BC PharmaCare’s Limited Coverage Drug Program. Click here to view the detailed medication criteria.
Tofacitinib is an oral targeted small molecule medicine (TSMM) that was issued a Notice of Compliance (NOC) from Health Canada on April 17, 2014. Tofacitinib in combination with methotrexate (MTX), is indicated for reducing the signs and symptoms of RA, in adult patients with moderately to severely active RA who have had an inadequate response to MTX. In cases of intolerance to MTX, physicians may consider the use of tofacitinib as monotherapy.
To learn more about BC PharmaCare’s coverage of arthritis medications, click here.
Want to know what Canada’s leading rheumatologists are thinking? Join us for our groundbreaking Facebook and Twitter “Live” event!
Canada’s arthritis consumer-patient organizations and groups to host Facebook and Twitter “Live” #CRArthritis Speaker’s Corner
Arthritis Consumer Experts (ACE) will be in Ottawa to attend the 2017 Canadian Rheumatology Association (CRA) Annual Scientific and Arthritis Health Professions Association Annual Meetings.
Powered by ACE and supported by representatives from the Arthritis Patient Advisory Board of Arthritis Research Canada, Canadian Arthritis Patient Alliance, Canadian Spondylitis Association, and Patient Partners, Arthritis Broadcast Network (ABN) will be interviewing keynote speakers, meeting attendees, patients living with arthritis, and disease experts. We invite you to participate in the Facebook and Twitter “Live” event. Like, share and retweet the live interviews, send us your comments or questions through Facebook and Twitter during the interviews.
Join the conversation at the Arthritis Broadcast Network Facebook page or Twitter (@ArthritisNetwrk) feed using #CRArthritis. Interviews will take place from Wednesday, February 8th until 12:00 pm, Friday, February 10th.